Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine
NCT03567304
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
28
Enrollment
OTHER
Sponsor class
Conditions
HIV-1-infection
Neurocognitive Dysfunction
Interventions
DRUG:
Rilpivirine 25 mg
Sponsor
Chiang Mai University